Navigation Links
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017

Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of

Increased Diagnosis Rates, According to a New Report from Decision


WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of emerging therapies, especially the long-acting beta2 agonist/inhaled corticosteroid combination drug class, will drive sales in the chronic obstructive pulmonary disease (COPD) drug market to more than $11 billion in 2017.

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that, among the emerging combination therapies, Novartis/Schering-Plough's indacaterol/mometasone and GlaxoSmithKline/Theravance's GW-642444/GW-685698 will experience annual growth of 60 percent and 71 percent, respectively, between 2012 and 2017 as a result of greater uptake of these once-daily, fixed-dose combination drugs. The market will also be driven by increased diagnosis rates in the next 10 years as the prevalent COPD population will rise by nearly 19 percent as a result of aging populations in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Although the COPD drug market in 2007 totaled just $6.6 billion, the market has yet to realize its maximum commercial potential, according to the report. Tapping into this great market opportunity will require significant improvements in diagnosis as well as the availability of more effective drug treatments, particularly therapies that address COPD-specific pathology.

"Although disease-modifying therapies are needed, treatments that provide symptomatic relief for COPD will remain the mainstay of treatment through 2017," said Regina Jammen, analyst at Decision Resources. "The market will shift from monotherapy use, as well as from the use of twice-daily dosed therapies, to combination treatments and once-daily dosed therapies as these drugs emerge from clinical development. Each major drug class will see the emergence of new once-daily dosed products, except for drug classes that are exclusively short-acting."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Computers help chemists fight emerging infections
2. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
3. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
4. GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
5. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
6. HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index
7. Targets on the horizon: Emerging therapies and novel targets
8. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
9. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
10. OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th
11. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
Breaking Medicine Technology: